Michael Crump - Concepedia

Author

Michael Crump

Princess Margaret Cancer Centre ORCID

Also Known As

Crump, M., Crump, M. R., Crump, Michael, M Crump, M. Crump, Michael Crump, Michael R Crump

580

Publications

17.8K

Citations

H-Index

101

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Toronto University Health Network BC Cancer Agency Queen's University

About

Michael Crump is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	67	4.9K
2	Health Sciences	20	28	1.3K
3	Public Health	2	2	104
4	Biomedical Engineering	2	2	23
5	Blood Transplantation	2	2	81

Michael Crump

182

Publications

16.8K

Citations

H-Index

Page 1

	Year	Citations
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial. B Coiffier, E.A. Osmanov, Xin Hong, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineRandomised Phase 3Follicular Lymphoma	2011	1.6K
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Michael Crump, Sattva S. Neelapu, Umar Farooq, Blood	2017	1.6K
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef, Journal of Clinical Oncology	2009	639
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Journal of Clinical Oncology	2011	630
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 Michael Crump, John Kuruvilla, Stephen Couban, Journal of Clinical Oncology	2014	454
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma Ralph M. Meyer, Mary Gospodarowicz, Joseph M. Connors, New England Journal of Medicine	2011	404
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Journal of Clinical Oncology	2021	392
Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome Richard Tsang, Mary Gospodarowicz, Melania Pintilie, Journal of Clinical Oncology	2003	384
Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer Nadine Tchen, Helen G. Juffs, Fiona Downie, Journal of Clinical Oncology	2003	378
Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis Lauren E. Abrey, Craig H. Moskowitz, Warren Mason, Journal of Clinical Oncology	2003	296

Page 1